Breaking Finance News

Liberum Capital issued a report on AstraZeneca PLC (LON:AZN), hiking its price target to 4,800.00GBX earlier today

Reporting a potential upside of 0.08%, Liberum Capital bumped up the target of AstraZeneca PLC (LON:AZN) to 4,800.00GBX

Boasting a price of 4,450.00GBX, AstraZeneca PLC (LON:AZN) traded -0.99% lower on the day. The last stock close price is down -9.46% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. AZN has recorded a 50-day moving average of 4,818.59GBX and a 200-day moving average of 4,863.31GBX. 190,856 shares of AZN traded hands, down from an average trading volume of 2,168,000

Recent Performance Chart

AstraZeneca PLC (LON:AZN)

AstraZeneca PLC has price-earnings ratio of 14.44 with a one year low of 3,996.00GBX and a one year high of 5,520.00GBX and has a market capitalization of 0 GBX.

A total of 29 brokers have issued a report on the company. 4 firms rating the stock a strong buy, 14 firms rating the stock a buy, 13 brokerages rating the stock a hold, 2 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell with a 12-month price target of 61.96GBX.

General Company Details For AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.